IP Library Granted Patent US 7,148,001
Granted Patent B2
US 7,148,001 · App. 10/007,779 · Granted Dec 12, 2006

Patent

Assignee: University of Washington
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,148,001
App. No.
10/007,779
Granted
Dec 12, 2006
Kind
B2
Abstract

Co-incubation of an amyloid protein with sulfated macromolecules as a method for the formation of amyloid plaques. The amyloid protein may be the beta-amyloid protein or the prion protein or the like. Amyoid plaque formation in one embodiment proceeds in vitro and desirably produces amyloid plaques that stain with Congo red and demonstrate a maltese-cross pattern when viewed under polarized light. The method also produces amyloid plaques that demonstrate an “amyloid star” appearance when viewed by transmission electron microscopy. An in vivo assay is also presented for selecting a candidate therapeutic agent for inhibiting or disrupting amyloid plaque deposition or persistence.

Claims (10)

1. A method for the formation of particular amyloid plaques, the method comprising in vitro co-incubation of beta-amyloid protein 1–40 (SEQ ID NO: 1) for at least 3–7 days at 30–45° C. with heparan sulfate, whereby spherical or compact shaped amyloid plaques are formed that demonstrate a Maltese-cross pattern when stained with Congo red and viewed under polarized light, and an amyloid star appearance when viewed by transmission electron microscopy, and further wherein the co-incubation is at a molar ratio of beta-amyloid protein to heparan sulfate within a range of 1:0.5 to 1:100.

2. The method of claim 1 wherein the molar ratio of beta-amyloid protein to heparan sulfate is about 1:5.

3. The method of claim 1 wherein the step of co-incubation of the amyloid protein with heparan sulfate is in distilled water or Tris-buffered saline (pH 7.0–7.4).

4. The method of claim 1 wherein the step of co-incubation has a duration of about 7 days.

5. The method of claim 1 wherein the step of co-incubation of the beta-amyloid protein with heparan sulfate occurs at about 37° C.

6. A method for the formation of particular amyloid plaques, the method comprising in vitro co-incubation of beta-amyloid protein 1–40 (SEQ ID NO: 1) for at least 3–7 days at 30–45° C. with heparan sulfate, whereby spherical or compact shaped amyloid plaques are formed that demonstrate a Maltese-cross pattern when stained with Congo red and viewed under polarized light, and an amyloid star appearance when viewed by transmission electron microscopy, and further wherein the co-incubation is at a weight ratio of beta-amyloid protein to heparan sulfate within a range of 1:0.4 to 1:100.

7. The method of claim 6 wherein the weight ratio of beta-amyloid protein to heparan sulfate is about 1:8 or 1:16.

8. The method of claim 6 wherein the step of co-incubation of the amyloid protein with heparan sulfate is in distilled water or Tris-buffered saline (pH 7.0–7.4).

9. The method of claim 6 wherein the step of co-incubation has a duration of about 7 days.

10. The method of claim 6 wherein the step of co-incubation of the beta-amyloid protein with heparan sulfate occurs at about 37° C.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 21, 2020
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 053566/0038 →
CONFIRMATORY LICENSE Recorded Jul 22, 2020
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 053284/0295 →
CONFIRMATORY LICENSE Recorded Sep 15, 2009
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023230/0531 →
Continuity (3)
Continuation 0926779500 · Mar 12, 1999
Provisional Application 6007792400 · Mar 13, 1998
Related Publication 20020168753A1 · Nov 14, 2002